secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0000950170-22-022488
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ono exercises option to Fate's HER2 CAR T-cell candidate; Fate to receive $12.5M
--------------------------------------------------------------------------------

- Ono exercised option to FT825/ONO-8250, triggering $12.5M option exercise fee to Fate.
- Fate and Ono to jointly develop and commercialize the candidate in the U.S. and Europe; Ono has exclusive rights elsewhere.
- Preclinical data showed broad, potent anti-tumor activity against HER2-low tumor cells.
- Fate eligible for additional clinical, regulatory, and commercial milestones plus tiered royalties on sales outside US/EU.
- Collaboration expanded to include a second solid tumor antigen program for preclinical development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000095017022022488/0000950170-22-022488-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000095017022022488/fate-20221107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-022488

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer